Read by QxMD icon Read

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Toshihiro Sera, Hiroaki Kuninaga, Kazuaki Fukasaku, Hideo Yokota, Masao Tanaka
BACKGROUND: In this study, we proposed an averaged airway model design based on four healthy subjects and numerically evaluated its effectiveness for predicting the airflow and particle transport through an airway. METHODS: Direct-averaged models of the conducting airways of four subjects were restored by averaging the three-dimensional (3D) skeletons of four healthy airways, which were calculated using an inverse 3D thinning algorithm. We simulated the airflow and particle transport in the individual and the averaged airway models using computational fluid dynamics...
February 13, 2019: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Jun Keng Khoo, A Bruce Montgomery, Kelly L Otto, Mark Surber, Jessica Faggian, Jason D Lickliter, Ian Glaspole
BACKGROUND: This clinical trial evaluated the pharmacokinetics and safety/tolerability of inhaled pirfenidone solution in volunteers and patients with idiopathic pulmonary fibrosis (IPF). METHODS: Forty-four adults in six cohorts consented to receive single doses of a 12.5 mg/mL pirfenidone solution or placebo to assess tolerability and pharmacokinetics. Cohorts 1, 2, and 3 (normal healthy volunteers [NHV]) (n = 6 active; n = 2 placebo in each cohort) received 25, 50, and 100 mg pirfenidone, respectively...
January 30, 2019: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Weiwei She, Zhengmin Mei, Haijin Zhao, Gang Li, Yun Lin
BACKGROUND: Airway remodeling is considered an important factor in refractory and uncontrollable asthma. Previous studies have confirmed that anti-nerve growth factor (NGF) antibody can ameliorate airway remodeling. However, whether nebulized inhalation of anti-NGF microspheres (NANM) can inhibit airway remodeling is not clear. The purpose of this study was to investigate the effects of NANM on ovalbumin (OVA)-induced airway remodeling, and the mechanisms involved. METHODS: Anti-NGF microspheres were produced using a polymer alloy method...
January 25, 2019: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Laetitia Bodet-Contentin, Antoine Guillon, Thierry Boulain, Jean-Pierre Frat, Denis Garot, Deborah Le Pennec, Laurent Vecellio, Stephan Ehrmann, Bruno Giraudeau, Elsa Tavernier, Pierre-François Dequin
BACKGROUND: Although nebulizing beta 2-agonists during noninvasive ventilation (NIV) could prove helpful, this administration route has to date never been studied in unstable chronic obstructive pulmonary disease (COPD) patients. We sought to demonstrate that salbutamol could be nebulized through an NIV circuit in COPD exacerbation and improve forced expiratory volume in 1 second (FEV1) as compared with placebo. PATIENT AND METHODS: This is a bench study to determine the optimal pattern of nebulization followed by a randomized double-blind parallel-group trial comparing salbutamol and placebo aerosols delivered during NIV to 43 intensive care unit patients...
December 27, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Karl Bass, Susan Boc, Michael Hindle, Kelley Dodson, Worth Longest
BACKGROUND: Computational fluid dynamics (CFD) provides a powerful tool for developing new high-efficiency aerosol delivery strategies, such as nose-to-lung (N2L) aerosol administration to infants and children using correctly sized aerosols. The objective of this study was to establish numerically efficient CFD solution methods and guidelines for simulating N2L aerosol administration to an infant based on comparisons with concurrent in vitro experiments. MATERIALS AND METHODS: N2L administration of a micrometer-sized aerosol (mass median aerodynamic diameter [MMAD] = 1...
December 15, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Samia M Omar, Nabila A Maziad, Nourhan M El-Tantawy
PURPOSE: Inhalable pulmonary delivery of isoniazid (INH) may improve the efficacy and reduce drug-resistant problem. METHOD: INH-loaded chitosan microparticles (Cs-Mps-1-3) were prepared as inhalable carrier for the previously prepared INH-loaded polyvinylpyrrolidone/polyitaconic acid nanoparticles (NPs) using spray-drying technique. Here, Cs-Mps-1-3 are composed of Cs: INH-loaded NPs: Free INH at w/w ratios (1:1:0), (1: 0:1), and (1:1:1), respectively. Subsequently, the prepared Cs-Mps-1-3 characterizations were studied...
December 8, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Markus Wolkenhauer, Kirsten Latza, Joachim Jung, Norbert Eckhard, Frank Götzmann
BACKGROUND: Currently, the equivalence and the substitutability of two inhaled medications are mainly driven by comparability of doses, in vitro performance, therapeutic equivalence and sameness, and handling of the inhalers. The packaging configuration is usually not considered as a factor. METHODS: Two capsule-based inhaled tiotropium-containing products that differ by their primary packaging configurations (blister versus bottle) were compared in terms of potential handling and resulting storage errors due to unintentional misuse...
December 4, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Jeffry G Weers, Yoen-Ju Son, Mark Glusker, Alfred Haynes, Daniel Huang, Nani Kadrichu, John Le, Xue Li, Richard Malcolmson, Danforth P Miller, Thomas E Tarara, Keith Ung, Andy Clark
This review discusses how advances in formulation and device design can be utilized to dramatically improve lung targeting and dose consistency relative to current marketed dry powder inhalers (DPIs). Central to the review is the development of engineered particles that effectively bypass deposition in the upper respiratory tract (URT). This not only reduces the potential for off-target effects but it also reduces variability in dose delivery to the lungs resulting from anatomical differences in the soft tissue in the mouth and throat...
November 27, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Edward M Kerwin, James F Donohue, Gary T Ferguson, Vaidyanathan Ganapathy, Ayca Ozol-Godfrey, Krithika Rajagopalan
BACKGROUND: Effective delivery of inhaled drugs in chronic obstructive pulmonary disease (COPD) depends on patients' ability to correctly use an inhalation device. Nebulized delivery may be appropriate for COPD patients who cannot coordinate breath with inhalation or generate adequate inhalational force. Until recently, long-acting muscarinic antagonists (LAMAs), used for maintenance treatment of COPD, were available for delivery only via handheld inhalers. Lonhala™ Magnair™ (glycopyrrolate inhalation solution) is a LAMA delivered via the eFlow® closed-system (eFlow CS) vibrating membrane nebulizer...
November 17, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Krishna Pudi, Gregory Feldman, Faisal Fakih, Peter Mack, Andrea Maes, Shahid Siddiqui, Earl St Rose, Colin Reisner
BACKGROUND: GFF MDI is a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler formulated using co-suspension delivery technology. This open-label, single-arm multicenter study (NCT02268396) evaluated the accuracy, reliability, and functionality of the GFF MDI AeroCount® dose indicator when used by patients with chronic obstructive pulmonary disease (COPD). PATIENTS AND METHODS: The study enrolled subjects (40-80 years of age) with an established clinical history (≥6 months) of COPD, who completed an electronic diary twice daily to record study-drug administration time, the number of actuations used, and pre- and post-dose dose indicator readings...
November 1, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Landon T Holbrook, Kirby L Zeman, Alyssa Burke, Ilona Jaspers, William D Bennett
BACKGROUND: Electronic cigarettes (ECIGs) are widely used, but their health effects are not well known. ECIG exposure is difficult to quantify, and a direct measurement of deposition would be beneficial to in vivo and in vitro toxicity studies. The aim of this study was to demonstrate effective radiolabeling of an ECIG. METHODS: A technetium-99m-labeled carbon ultrafine (TCU) aerosol was generated and introduced to a fourth-generation ECIG before nucleation and aerosol formation...
October 30, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
James Verco, William Johnston, Michael Baltezor, Philip J Kuehl, Andrew Gigliotti, Steven A Belinsky, Anita Lopez, Ronald Wolff, Lauren Hylle, Gere diZerega
BACKGROUND: Inhaled chemotherapeutics may enhance pulmonary drug exposure to malignant lesions in the lung without substantially contributing to systemic toxicities. The pharmacokinetic profile of inhaled submicron particle paclitaxel (NanoPac® ) in healthy rodent plasma and lung tissue is evaluated here to determine administration proof-of-principle. METHODS: Healthy male Sprague Dawley rats received paclitaxel in one of three arms: intravenous nab-paclitaxel at 2...
October 25, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Oihana Basabe-Burgos, Jakub Zebialowicz, Guido Stichtenoth, Tore Curstedt, Peter Bergman, Jan Johansson, Anna Rising
BACKGROUND: Pulmonary surfactant spreads rapidly over the airway epithelium, a property that could be harnessed to transport drugs into the lungs. For efficient drug delivery, an interaction between pulmonary surfactant and the drug to be administered is likely needed. On the other hand, the interaction should not compromise the activity of surfactant or the drug once delivered in vivo. The antibiotics gentamicin (an aminoglycoside) and polymyxin E represent drugs that could benefit from being delivered directly to the lung, thereby increasing local concentrations and reducing systemic side effects...
October 19, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Rain Jõgi, Satu Lähelmä, Mikko Vahteristo, Anita Happonen, Jussi Haikarainen
BACKGROUND: The Easyhaler® device-metered dry powder inhaler containing Salmeterol and Fluticasone propionate (S/F) has been developed for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD). We report two studies which evaluated the in vitro flow rate dependence of delivered dose (DD) and fine particle dose (FPD) of S/F Easyhaler versus Seretide Diskus® . METHODS: A randomized controlled trial (RCT) assessed inspiratory flow parameters of S/F Easyhaler and Seretide Diskus in subgroups of patients with asthma (children, adolescents and adults, and elderly) and in COPD patients...
October 9, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Johann Christian Virchow, Gianluigi Poli, Christiane Herpich, Claudius Kietzig, Hilke Ehlich, Daniela Braeutigam, Knut Sommerer, Sabine Häussermann, Fabrizia Mariotti
BACKGROUND: This study evaluated the lung deposition and the distribution pattern in the airways of a fixed combination of beclometasone dipropionate (BDP) and formoterol fumarate (FF) (100/6 μg) delivered as an extrafine dry powder formulation (mass median aerodynamic diameter, MMAD (μm) BDP = 1.5; FF = 1.4) through the NEXThaler® device in healthy subjects, asthmatics, and patients with COPD. METHODS: Healthy subjects (n = 10), asthmatic patients (n = 9; 30%≤FEV1 < 80%), and COPD patients (n = 9; FEV1 /FVC ≤70%, 30%≤FEV1 < 50%) completed this open-label, single administration (inhalation of four actuations) parallel group study...
October 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Beatriz Herrero-Cortina, Victoria Alcaraz, Jordi Vilaró, Antoni Torres, Eva Polverino
BACKGROUND: The role of hyaluronic acid plus hypertonic saline (HA+HS) as a mucoactive treatment in patients with bronchiectasis is still unknown. This study evaluated whether HA+HS solution enhances similar sputum quantity with better safety profile than HS alone in patients with bronchiectasis. METHODS: In this double-blind randomized crossover trial, three solutions (7% HS; 0.1% HA +7%HS; and 0.9% isotonic saline, IS) were compared in outpatients with bronchiectasis and chronic sputum expectoration...
October 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Bruno Sposato
No abstract text is available yet for this article.
October 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Luciana Alcoforado, Armèle Dornelas de Andrade, Joaquin L Herraiz, Simone Cristina Soares Brandão, Jacqueline de Melo Barcelar, James B Fink, Jose G Venegas
INTRODUCTION: Manual analysis of two-dimensional (2D) scintigraphy to evaluate aerosol deposition is usually subjective and has reduced sensitivity to quantify regional differences between central and distal airways. AIMS: (1) To present a method to analyze 2D scans based on three-dimensional (3D)-linked anatomically consistent regions of interest (ROIs); (2) to evaluate peripheral-to-central counts ratio (P/C2D ) and penetration indices (PIs) for a set of 16 subjects with moderate-to-severe asthma; and (3) to compare the reproducibility of this method against one with manually traced ROIs...
October 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Rym Mehri, Weiquan Tang, Edgar A Matida, Edward P C Lai
BACKGROUND: Chelating agents such as diethylenetriamine pentaacetic acid (DTPA) can be used as a decorporation drug in the zinc (Zn) form to treat internal radioactive contamination after exposure to plutonium or americium in a nuclear accident. Although Zn-DTPA is normally administered intravenously, inhalation of Zn-DTPA in aerosol form is a better route for direct delivery to the lungs. This work investigates the feasibility of synthesizing Zn-DTPA from three common chemicals and aerosolizing it using a jet or ultrasonic nebulizer...
October 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Merja Kirjavainen, Leena Mattila, Mikko Vahteristo, Jani Korhonen, Satu Lähelmä
BACKGROUND: Easyhaler® dry powder inhaler (DPI) containing salmeterol and fluticasone propionate was developed for the treatment of asthma and chronic obstructive pulmonary disease. Three different Salmeterol/fluticasone Easyhaler test products (Orion Pharma, Finland) were compared against the reference product Seretide® Diskus® DPI (GlaxoSmithKline, United Kingdom) to study whether any of the test products are bioequivalent with the reference. METHODS: Open and randomized pharmacokinetic four-period crossover study on 65 healthy volunteers was performed in a single center to compare the lung deposition and total systemic exposure of salmeterol and fluticasone propionate after administration of single doses (two inhalations of 50/500 μg/inhalation strength) in fasting conditions...
October 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"